Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

on for future payments to Palatin, other than for previously

incurred costs not yet reimbursed and approved expense reimbursements

related to the wind-down of the collaboration.

-- Advancement of a lead compound through the preclinical stages resulting

in the anticipated filing of an Investigational New Drug Application

for a synthetic compound that mimics natriuretic peptides for the

treatment of patients with congestive heart failure in the second half

of calendar year 2007.

-- The completion of an exploratory at-home Phase 2B clinical trial in

pre- and postmenopausal women. We are in the final stages of compiling

the data and anticipate releasing the results of this trial later this

month.

LICENSE, GRANTS AND CONTRACTS

For the quarter ended June 30, 2007, Palatin recognized revenue under its collaboration agreement with King of $1.8 million, which includes King's share of bremelanotide development costs, and $0.7 million of contract revenue related to its February 2007 collaboration with AstraZeneca. In the comparable quarter of 2006, Palatin recognized $4.9 million of contract revenue from King, reflecting significantly higher cost reimbursement revenue resulting from Palatin's clinical study activities.

COSTS AND EXPENSES

Total operating expenses for the quarter ended June 30, 2007 were $9.1 million versus $13.2 million for the comparable quarter of 2006, reflecting lower development costs of bremelanotide following the completion of two Phase 2B clinical trials in patients with ED, which were partially offset by other research and development spending and higher stock-based compensation charges.

CASH POSITION

Palatin's cash, cash equivalents and investments totaled $33.8 million as of June 30, 2007, compared to $30.7 million at June 30, 2006, as current year operating expenses were largely offset by net proceeds from the February 200
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015  In the farthest reaches of ... the Matsés tribe came together in a quest to ... The gathering, held in May in a remote village ... Brazil , concluded over two years work and ... Encyclopedia ever written by an Amazonian tribe. The 500-page ...
(Date:7/7/2015)... ... ... uBiome, the leading microbial genomics company, is offering talented researchers with big ... laboratory analysis. The goal is to fast-track a study with the greatest potential to ... dashboard, enabling them to view and compare the results of their study, as well ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... CentrePoint Study Admin system was developed to solve many of the ... analysis, particularly within studies that involve multiple clinical sites and/or remote data coordination ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Personalized Medicine, recently hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting ... with Proove Biosciences’ executive Research and Development team to discuss new clinical practice ...
Breaking Biology Technology:Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 2Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 3Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 4uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3
... July 11 PURE Bioscience (Nasdaq:,PURE) announced today that ... to ring the closing bell at the NASDAQ Stock ... commemorate PURE,s return to the,NASDAQ stock market on April ... live webcast of the closing ceremony will begin at ...
... , The white blood cells in our body ... in leukemia, the formation of white blood cells is ... cells multiply out of control without fully maturing. This ... patients more susceptible to infections. T-ALL, a particular form ...
... July 10 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced ... financial results on Thursday, July 31, 2008 at approximately,4:00 ... by a,conference call at 4:30 p.m. ET. Hank Nordhoff, ... president, finance, and,chief financial officer, will host the call., ...
Cached Biology Technology:PURE Bioscience CEO to Ring NASDAQ Closing Bell 2PURE Bioscience CEO to Ring NASDAQ Closing Bell 3Not the protein, but its location in the cell, determines the onset of leukemia 2Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call 2
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... of North Carolina at Chapel Hill chemists have ... of creating the world's tiniest manufactured particles for ... human body.Adapting technology pioneered by the electronics industry ... for the first time how to create particles ...
... decision-making tools for public health officials. As demonstrated ... models can be useful in two ways: they ... and they can allow the comparison of alternative ... assumptions that may systematically bias their predictions, say ...
... biology researchers at Virginia Tech have enhanced the abilities ... blows to cancer cells. The man-made molecular complexes enter ... cause the cell to change. The new supermolecules have ... control over the range of light frequencies that can ...
Cached Biology News:Breakthrough: Scientists create world's tiniest organic particles 2Breakthrough: Scientists create world's tiniest organic particles 3Field of beams - Novel system uses polarized light pulses to reveal crop health 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3
... This kit allows for quick and reproducible ... plate. The system is more reproducible than regular ... the protein A/G agarose without disrupting the agarose ... Catch and Release is reversible, and elution of ...
... Oligo Microarray Kit (V2), 2 x ... characterize expression of many thousands of ... during important biological processes. Each microarray ... known ORFs from the S288C strain ...
... Successful biomarker discovery projects require screening ... to distinguish clinically relevant data from ... Data Manager is now available to ... tracking and data flood inherent to ...
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
Biology Products: